





Creso Pharma is becoming

GLOBAL HEALTH

Art, Science and Natural Products.

Combining traditional plant-derived remedies with modern scientific expertise to bring safe, natural & efficacious products to market for a growing group of source-conscious consumers. As we continue to integrate processes, products, brands and talent across our portfolio, we intend to mark this pivotal moment with a new name that represents the global ambitions of the organization."

- Will Lay, CEO

Subject to shareholder approval, Creso Pharma will become Melodiol Global Health.

Melodiol GLOBAL HEALTH



Executive Summary

EXECUTIVE SUMMARY

Melody: Musically satisfying, often the most memorable part of a song **Diol:** Common chemical structure of organic compounds

Relocion GLOBAL HEALTH

Creso is pleased to provide an update on go-forward strategy to investors

Pivotal moment in Creso's history marked by name change

Changes in corporate board with a focus on improving independence

Significant focus on achieving cash flow positive state



Our Renewed Mission

Melodiol GLOBAL HEALTH



As we optimize revenue growth and profitability across the portfolio, we intend to focus on 4 core objectives in order to drive our long term strategies:



Beyond marking this pivotal moment in our history, our name change represents our renewed mission and positions our long term strategies for success.

INCREASED BOARD INDEPENDENCE



James Ellingford

Non-executive Chairman

Ex President of an international publicly listed billion-dollar business with its headquarters in Geneva, Switzerland and New York, USA



William Lay Executive Director & CEO

Former investment banker and previously led or supported >C\$5 billion of M&A deals as Associate Director at Canopy Growth



Bruce Linton*

Non-executive Director

Co-founder and former Chairman of Canopy Growth Corporation, world-leader in cannabis and psychedelics



Micheline MacKay

Executive Director

Managing Director at Mernova, 22 years of experience in regulatory environments



Jodi Scott

Executive Director

President of US Operations, co-founder & CEO of Sierra Sage, MS Health Psychology, product developer & brand builder



Boaz Wachtel

Non-executive Director

Leading Medical cannabis expert, co-founder and former MD of Phytotech Medical, Australia's first publicly traded medical cannabis company



Ben Quirin* Non-executive Director

Former Managing Director, APAC at Canopy Growth Corporation, 20+ years global leadership experience CONTINUING TO INCREASE THE DEPTH AND INDEPENDENCE OF OUR BOARD AS WE PURSUE OUR RENEWED MISSION.

17% 29% PRIOR POST




Board Independence



Strategic Imperative

8



SHARED SERVICES

As we continue to invest in revenue growth across the portfolio, we will begin to leverage the **collective strengths and efficiencies** of the assembled group of companies to drive profitability.

GLOBAL SALES & DISTRIBUTION

- E-commerce strength
- Sales strength
- Distribution efficiency

FINANCE & ADMIN SHARED SERVICES


- Access to Capital
- M&A Integration Capabilities
- Efficient Operations
- Marketing, Branding



- MANUFACTURING
- Product Quality/Efficacy
- Strong Supply Chain Function
- Ongoing Product Innovation

ENABLING FUTURE M&A






FUTURE ACQUISITION TARGETS

By continuing to drive efficiencies, our aim is to absorb less of each M&A target's existing cost structure with every subsequent acquisition, allowing a higher % of gross margin to flow directly to the consolidated entity for redeployment.

LEVERAGING OUR STRENGTHS

Creso's M&A and integration expertise, along with the growing strength of our shared services, positions us well to take advantage of forecasted category consolidation in the years ahead.







Creso Pharma will provide further communication to shareholders regarding shareholder approval for changing the Company's name to Melodiol Global Health

This presentation has been authorized for release by the Disclosure Committee of the Board.





